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ABSTRACT: A drug delivery system designed speciﬁcally for
oligonucleotide therapeutics can ameliorate the problems
associated with the in vivo delivery of these molecules. The
internalization of free oligonucleotides is challenging, and
cytotoxicity is the main obstacle for current transfection
vehicles. To develop nontoxic delivery vehicles for eﬃcient
transfection of oligonucleotides, we designed a self-assembling
peptide amphiphile (PA) nanosphere delivery system deco-
rated with cell penetrating peptides (CPPs) containing multiple arginine residues (R4 and R8), and a cell surface binding peptide
(KRSR), and report the eﬃciency of this system in delivering G-3129, a Bcl-2 antisense oligonucleotide (AON). PA/AON
(peptide amphiphile/antisense oligonucleotide) complexes were characterized with regards to their size and secondary structure,
and their cellular internalization eﬃciencies were evaluated. The eﬀect of the number of arginine residues on the cellular
internalization was investigated by both ﬂow cytometry and confocal imaging, and the results revealed that uptake eﬃciency
improved as the number of arginines in the sequence increased. The combined eﬀect of cell penetration and surface binding
property on the cellular internalization and its uptake mechanism was also evaluated by mixing R8-PA and KRSR-PA. R8 and R8/
KRSR decorated PAs were found to drastically increase the internalization of AONs compared to nonbioactive PA control.
Overall, the KRSR-decorated self-assembled PA nanospheres were demonstrated to be noncytotoxic delivery vectors with high
transfection rates and may serve as a promising delivery system for AONs.
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■ INTRODUCTION
RNA interference mechanisms have attracted much attention in
the recent decade, and advances in the design and development
of oligonucleotides and drug delivery systems have rendered it
possible to employ interfering RNAs for therapeutic purposes.
Oligonucleotide therapeutics, which include antisense oligonu-
cleotides (AONs), siRNAs (small interfering RNAs), CpG
oligonucleotides, and aptamers, are a class of drugs noted for
their exceptionally high target speciﬁcity facilitated by the base
pairing between the target mRNA and the therapeutic
oligonucleotide. Hence, oligonucleotide drugs overpower
traditional small molecule drugs on account of the speciﬁty of
the binding, which is rendered by base pairing between target
mRNA and therapeutic oligonucleotide.1 Within this class,
AONs and siRNAs (expression modulating oligonucleotides)
are short, synthetic nucleic acids designed to bind a target
transcript and decrease the expression of the corresponding
gene. The target gene is typically one that is overexpressed in a
speciﬁc disease (cancer, cardiovascular, or metabolic), and its
knock-down allows the diseased tissue to resume its normal
function.2,3
Despite its relatively recent discovery, the simplicity and
eﬃciency of the RNA interference process have led to the rapid
proliferation of oligonucleotide-based drug candidates, and
several clinical trials have been conducted to evaluate their
feasibility for use as therapeutics. However, only two antisense
oligonucleotide drugs have made it through the pipeline:
Fomivirsen (Vitravene) and Mipomersen (Kynamro) were
approved in 1998 and 2013, respectively. The remaining clinical
trials were terminated without meeting their end points,
principally as a result of ineﬃcient biodistribution or poor
pharmacodynamic and pharmacokinetic properties.4,5 In
addition to the drawbacks regarding their in vivo eﬃciency, a
second major obstacle in oligonucleotide delivery is the poor
cell penetration capability of oligonucleotide-based drugs,
which stems from their heavily negative charges.6 The negative
charges of the oligonucleotide and the cell membrane act to
repel the drug from the membrane, which complicates the
mechanism of cellular internalization. Given the disadvantages
of naked oligonucleotide delivery and the undesired properties
of the free drug, an eﬃcient delivery strategy is required for
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oligonucleotide-mediated therapeutic eﬀorts. Several delivery
systems have been developed for this purpose using both viral
delivery methods and nonviral delivery systems such as cationic
lipids or cationic polymer systems.7 In the case of polymer-
based carrier systems, the transfection eﬃciency of the cationic
polymer was found to be correlated with its molecular weight,
which is also correlated with carrier toxicity. In addition,
polymers are synthesized with substantial variations in
molecular weight, which complicates quality control and
creates batch-to-batch variations. Cationic lipids also suﬀer
from high toxicity due to their strongly positive charge. In
response to the problems associated with cationic delivery
systems, nontoxic liposomes (anionic and neutral liposomes)
were proposed as alternative delivery agents, but the trans-
fection eﬃciency of these liposomes and other noncationic
systems (polymers, nanoparticles) were found to be too low for
eﬀective delivery. Consequently, the cellular internalization of
these systems is often enhanced through surface modiﬁcation
methods.8
Cell-penetrating peptides (CPPs) are positively charged
peptide sequences that facilitate the passage of their cargo
through the cell membrane, and they are frequently used for
the functionalization of drug carriers. There are two strategies
for CPP-mediated oligonucleotide delivery based on covalent
and noncovalent binding of the peptide to the oligonucleotide.
Early studies were mostly based on the conjugation of the CPP
to oligonucleotides in the form of peptide nucleic acids (PNA)
and phosphorodiamidate morpholino oligomers (PMO).
Noncovalent strategies, in contrast, turned out to be more
advantageous not only due to their simplicity, but also for the
low concentrations of oligonucleotide and CPP required for the
system to be eﬀective. CPP-functionalized drug delivery
systems serve to protect the oligonucleotide from enzymatic
degradation and allow usage of low doses of the oligonucleotide
drug to reach therapeutic eﬃciency, which in turn decreases
toxicity and oﬀ-target eﬀects.9 Noncovalent functionalization of
TAT,10 penetratin,11 and oligoarginine CPPs12,13 was studied
for oligonucleotide and siRNA delivery. These systems are
advantageous due to their high transfection eﬃciency; however,
concerns were raised regarding the potential toxicity and
nonspeciﬁcity of these carrier systems, especially in light of the
ﬁndings that the CPPs in question may show toxic eﬀects even
at very low concentrations.14 It is therefore essential to design
CPP-functionalized delivery systems to enhance membrane
permeability while eliminating potential side eﬀects. To this
end, we designed a delivery system using peptide amphiphiles,
bioinspired molecules that have the ability to self-assemble into
a predetermined structure. The structures of peptide
amphiphiles are highly variable, and this versatility allows
them to be engineered for diﬀerent purposes, facilitated
through the use of peptide sequences known to play roles in
diﬀerent metabolic functions, such as membrane penetration,
receptor binding, or proteoglycan binding. In this study, we
designed self-assembling peptide amphiphiles incorporating
two distinct types of bioactive peptide sequences: arginine rich
cell penetrating peptides (R4 and R8) and a cell surface
proteoglycan binding peptide (KRSR).15 We then used these
peptides decorated with two types of internalization-mediating
signals to increase membrane penetration and the transfection
eﬃciency of an oligonucleotide drug.
■ MATERIALS AND METHODS
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-
butoxycarbonyl (Boc) protected amino acids, [4-[α-(2′,4′-
d imethoxyphenyl) Fmoc- aminomethyl]phenoxy]-
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin),
and 2-(1H-benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexa-
ﬂuorophosphate (HBTU) were purchased from NovaBiochem.
Lauric acid and N,N-diisopropylethylamine (DIEA) were
purchased from Merck. All other chemicals were purchased
from Alfa Aesar and Sigma-Aldrich and used as provided. All
water used was deionized water with a resistance of 18 MΩ cm
(Millipore Milli-Q). Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM), fetal bovine serum (FBS), penicillin−streptomycin
(PS), and trypsin were purchased from Gibco, Life
Technologies. Lipofectamine and Alamar Blue were purchased
from Invitrogen; uptake inhibitors were purchased from Sigma.
Bcl-2 antisense oligonucleotide (G-3129, Genasense) and
ﬂuorescein-6-amide (FAM) labeled antisense oligonucleotide
having the sequence: 5′-TCTCCCAGCGTGCGCCAT-3′
were donated by Genta Inc. G4126, the mismatch (MM)
control with a sequence 5′-TCTCCCAGCATGTGCCAT-3′,
was used in expression studies.
Synthesis of Peptide Amphiphiles. Peptide amphiphiles
were synthesized with the standard Fmoc solid phase peptide
synthesis method. As a solid support, Rink Amide MBHA (0.59
mmol g−1 loading) resin was used. Dissolved Fmoc protected
amino acid activated with HBTU, and DIEA was coupled to
resin or previous amino acid for 3 h. To monitor the
completeness of coupling, Kaiser test was performed after
each reaction. Deprotection of Fmoc protecting groups was
done by adding 20% piperidine in DMF and allowing to shake
for 20 min. The resin was then treated with 10% acetic
anhydride for 30 min to block unreacted amine groups. Peptide
amphiphile was separated from the solid phase by using
cleavage protocol where peptide was treated with triﬂuoroacetic
acid (TFA)/triisopropylsilane (TIS)/water at a ratio of
95:2.5:2.5 for 2 h. Peptide amphiphiles were precipitated with
diethyl ether, and the precipitate was collected with
centrifugation, dissolved in water, and freeze-dried. The
peptides were characterized by reverse-phase high-performance
liquid chromatography (HPLC) on an Agilent 6530 accurate-
Mass Q-TOF LC/MS equipped with an Agilent 1200 HPLC. A
Phenomenex Luna 3 μ C8 100A (50 × 3.00 mm) column and a
water (0.1% formic acid)/acetonitrile (0.1% formic acid)
gradient were used as stationary phase and mobile phase,
respectively.
Circular Dichroism (CD). CD analysis was performed by J-
815 Jasco spectrophotometer with an integration time of 4 s,
bandwidth of 1 nm, and data pitch of 0.1 nm. PAs were
dissolved in water to a ﬁnal concentration of 200 μM. PA/AON
samples were prepared to have a molar ratio of 30:1 PA/AON.
Quartz cuvettes with 1 mm path lengths were used for
measurements. An average of three readings were recorded;
ellipticity was converted to molar ellipticity with the unit degree
cm2 dmol−1.
Transmission Electron Microscopy (TEM). PA samples
were prepared with 0.05% (w/v) PA solution, and PA/AON
complexes were prepared to have ﬁnal concentrations of 0.05%
(w/v) PA to 50 ng/μL AON. Solutions were dropped onto
200-mesh copper grids. After 5 min, samples were removed,
and grids were stained with 2% uranyl acetate for 3 min. After
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washing, samples were air-dried, and images were obtained by a
FEI Tecnai G2 F30 TEM at 200 keV.
Maintenance of Cells and Transfection with PA/AON
Complexes. MCF-7 cells were maintained in DMEM with
10% FBS and 1% PS and passaged at cell conﬂuency between
80 and 90% using trypsin−ethylenediaminetetraacetic acid
(EDTA). PA/AON complexes were prepared in water for
AON transfection to have molar ratios of 30:1 (PA/AON).
MCF-7 cell line was used as a breast cancer cell model for
delivering Bcl-2 antisense oligonucleotide.
Cellular Internalization of PA/AON Complexes. For
confocal microscopy, 4 × 104 MCF-7 cells per well were seeded
in 24-well plates in standard medium. After 24 h, medium was
discarded, serum-free medium was added, and PA/AON
complexes were administered to have a ﬁnal concentration of
30 μM PA and 1 μM AON. After 24 h of incubation, cells were
washed with phosphate-buﬀered saline (PBS) three times, ﬁxed
with 4% paraformaldehyde (PFA), and stained with phalloidin
and TO-PRO-3. Cells were then visualized by a laser scanning
confocal microscope (LSM 510, Zeiss).
Flow Cytometry. For ﬂow cytometry, 2 × 104 MCF-7 cells
per well were seeded in 96-well plates with standard medium.
After 24 h of cell seeding, medium was changed to serum-free
medium. PA/AON complexes were prepared and administered
to have ﬁnal concentrations of 30 μM PA and 1 μM AON.
Cells were incubated for 24 h and suspended by trypsinization.
After washing twice with PBS and centrifugation at 1500 rpm
for 5 min, cells were resuspended in PBS. Cells were analyzed
by a Guava easyCyte (Milipore) ﬂow cytometer. By using
nontreated control, cells were gated by SSC (side scatter
channel) and FSC (forward scatter channel). Fluorescence
intensity of FAM-AON was measured by the green channel.
Mechanisms of Internalization. To study the internal-
ization mechanism of PA/AON complexes, chemical inhibitors
were used to inhibit speciﬁc internalization pathways. Aliquots
of 2 × 104 MCF-7 cells per well were seeded in 96-well plates
with standard medium. After 24 h of seeding, medium was
changed to serum-free medium, and inhibitor solutions were
administered at ﬁnal concentrations of 100 μM amiloride, 20
μM dynasore, 0.2 μg/mL chlorpromazine, and 10 μg/mL
nystatin. After 1 h of incubation with inhibitors, PA/AON
complexes were prepared and administered at ﬁnal concen-
trations of 30 μM PA and 1 μM AON. Cells were incubated for
24 h and suspended with trypsinization. After being washed
with PBS twice, cells were collected and analyzed with a ﬂow
cytometer as described above.
Gene Expression Analyses. Aliquots of 4 ×105 MCF-7
cells per well were seeded in 6-well plates with standard
medium. After 24 h, medium was discarded, and PA/AON and
PA/MM complexes were administered in serum-free medium
at ﬁnal concentrations of 60 μM PA and 2 μM oligonucleotide.
Complexes were incubated for 24 h, except R8-PA, which was
administered at 20 μM concentration and incubated for 4 h due
to its toxicity. Lipofectamine control, AON-only, and MM
groups were also administered at a ﬁnal concentration of 2 μM
oligonucleotide. Lipofectamine was used according to the
manufacturer’s instructions. After incubation, cells were washed
with PBS, and RNA was extracted with TRIzol reagent.
Expression levels of Bcl-2 were investigated by a Biorad C1000
thermal cycler using a one step qRT-PCR kit (Invitrogen).
Expression levels were normalized to GAPDH.
Figure 1. (a) Chemical representation of PAs used in this study: lauryl-P4GK-Am (K-PA), lauryl-P4GKRSR-Am (KRSR-PA), lauryl-P4R4-Am (R4-
PA), and lauryl-P4K2R8-Am (R8-PA). (b) Circular dichroism spectra of PAs and PA/AON complexes.
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■ RESULTS AND DISCUSSION
Design of Peptide Amphiphiles. Peptide amphiphiles
were designed with an alkyl tail, a proline-rich sequence, and a
bioactive unit (Figure 1). Proline residues, known as β-sheet
breakers, were used to force the ﬁnal self-assembled structure to
have a spherical shape.16 The driving forces for self-assembly
were H-bonding and hydrophobic and electrostatic inter-
actions. As a result of the self-assembly process, the
hydrophobic alkyl tails were buried to the interior of the
structure, and the bioactive peptide sequences were presented
on the exterior. Peptide amphiphiles were decorated with two
diﬀerent polyarginine peptides, tetraarginine (R4) and
octaarginine (R8), to enhance their cellular internalization.
Arginine-rich cell-penetrating peptides were shown to be
eﬀective in cargo delivery in numerous studies.17 On the
basis of the knowledge that the peptide−proteoglycan
interactions mediate cellular internalization,18 in addition to
polyarginine residues, we designed our cell surface-binding
peptide with the sequence KRSR, which follows the general
heparin-binding sequence BBXB (the Cardin−Weintraub
motif). This sequence was found to be consensus in heparin
binding peptides and proteins15 and has been proposed as a
potential common-receptor binding peptide for drug delivery.19
In addition to the proteoglycan binding propensity of KRSR
peptide, its basic nature also fortiﬁes the binding to the cell
surface membrane and enables translocation of the cargo
similarly to other cell-penetrating peptides. K-PA was used as a
nonbioactive PA control. Solid phase peptide synthesis method
was used to synthesize all peptide amphiphiles, and they were
analyzed by liquid chromatography and mass spectrometry
(Figure S1, Supporting Information).
Characterization of the PA/AON Complexes. The
secondary structure, morphology, size, and zeta potential of
peptide amphiphiles and peptide amphiphile−oligonucleotide
complexes were characterized to gain insight into their
biophysical, morphological, and physical features. Secondary
structures of PAs were determined by CD (Figure 1). All PAs
and PA/AON complexes displayed a negative peak around 200
nm, which revealed that they exhibited random coil structure.16
The morphology of PAs and PA/AON complexes was
observed by TEM imaging (Figure 2). According to TEM
images, all bare peptide amphiphiles formed spherical
nanostructures. Their sizes varied between 15 and 45 nm
depending on the peptide sequence except R8/KRSR mixture.
Upon complexation with AON, there was a tendency for the
nanospherical particles to increase their size, especially in the
R4-PA/AON and KRSR-PA/AON samples. The size increase
might be explained by the fusion of peptide amphiphile micelles
with oligonucleotides, or these structures might be micellar
aggregates of peptide amphiphiles formed due to the presence
of oligonucleotide. R4-PA formed more elongated spheres in
the presence of AON, which were typically clustered together.
Compared to R4-PA, KRSR-PA/AON formed more regular
spherical structures that did not aggregate. In contrast to the
general tendency to increase in size, R8-PA formed smaller
nanospherical structures when complexed with AONs. Since
each PA contains a diﬀerence sequence, the size changes
observed in AON-complexed PAs are attributed to the variance
in PA-AON interactions, which are expected to be mediated
primarily through the peptide moieties.
The hydrodynamic sizes of peptide amphiphiles were
investigated with dynamic light scattering measurements, and
the unmodiﬁed PA size was found to be around 70 nm in
diameter, which is greater than the sizes in TEM images
(Figure S2, Supporting Information). The discrepancy in size
measurements can be attributed to the diﬀerences between the
two measurement methods. While dried samples were used for
TEM imaging, which may cause shrinking of the micelles,
dynamic light scattering measures the size of highly hydrated
micelles.20 When PAs were complexed with AON, K-PA/AON,
R8-PA/AON, and R8/KRSR/AON, they formed similarly sized,
small spherical nanostructures around 70 nm in diameter,
whereas complexation with AON increased the size of KRSR-
PA and R4-PA/AON, which was also the case in transmission
electron micrographs.
Zeta potential of the bare PA and PA/AON complexes was
measured by using Zetasizer, and the results are provided in
Table S1 of the Supporting Information. Unmodiﬁed peptide
amphiphiles were positively charged as a result of the presence
of lysine and arginine residues. The design of PAs was based on
the idea that introducing positive charges to the system would
facilitate complexation between the PAs and the AONs through
electrostatic interactions. The charge of K-PA, which contains
only one lysine as a basic amino acid, was slightly positive. PAs
containing more than one basic amino acid (R4-PA, KRSR-PA,
and R8-PA) had greater zeta potentials, while R8-PA, with its
octoarginine residue, had the highest zeta potential. After
complexation with AON, zeta potentials of PAs decreased,
Figure 2. TEM images of PAs and PA/AON complexes (scale bars: 50 nm).
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likely due to the negative charge imparted by the oligonucleo-
tide itself.
Biocompatibility of the PA and PA/AON Systems. The
viability of MCF-7 cells incubated with PAs was investigated
after 24 h (Figure S3, Supporting Information). K-PA, KRSR-
PA, and R4-PA were found to be biocompatible at 200 μM,
which was far above the eﬀective dose (30−60 μM) used for
our in vitro experiments. R8-PA, on the other hand, was
cytotoxic at 50 μM. Polyarginine CPPs are known to be
internalized more as the number of arginines in the sequence is
increased, which in turn increases the toxicity of the peptide.21
Toxicity therefore depends on the arginine number, cell type,
and incubation period. In general, the IC50 value of
polyarginines with more than eight arginines in their sequence
was found to be between 10 and 100 μM21,22 for short
incubation times. In the present study, we found the IC50 of
peptide amphiphile containing R8 to be around 50 μM after 24
h of incubation, which indicates that the toxicity of R8-PA stems
from the presence of oligoarginine in the sequence.
Cellular Internalization Analyses. The cellular internal-
ization of PA/AON complexes was monitored by confocal
microscopy after 24 h of incubation (Figure 3). The
internalizations of KRSR-PA/AON (Figure 3c,d), R4-PA/
AON (Figure 3e,f), and R8-PA/AON (Figure 3g,h) were
observed to be more eﬀective compared to K-PA/AON (Figure
3a,b). The internalization of R8-PA/AON was signiﬁcantly
greater than control even at low concentrations of R8-PA (3
μM). The internalization of a R8/KRSR/AON complex (Figure
3i,j) containing 1 μM R8-PA and 3 μM KRSR-PA was also
signiﬁcantly greater than the control. The combination of the
two PA molecules, one binding to cell surface heparins and the
other penetrating the cell membrane, was therefore observed to
be more eﬀective for cellular internalization.
The uptake was also quantiﬁed by ﬂow cytometry, in which
the ﬂuorescence of FAM-AON was quantiﬁed in MCF-7 cells
incubated with PA/AON complexes for 24 h (Figure 4). The
internalization of KRSR-PA/AON and R4-PA/AON was found
to be slightly increased compared to K-PA. The uptake of R8-
PA/AON complex, administered at the same concentration
with other PA/AON complexes, was particularly drastic. When
R8-PA and R4-PA were compared, cellular internalization was
observed to increase as the number of arginines in the sequence
increased, which is consistent with previous results.21
Interestingly, the internalization eﬃciency of the combina-
tion of R8/KRSR/AON was almost the same as R8-PA/AON,
although a lower amount of R8-PA was present. Thus, by
combining the noncytotoxic properties of KRSR-PA with the
high internalization capacity of R8-PA, the combination of R8-
PA and KRSR-PA might be an eﬀective oligonucleotide delivery
system with its remarkable internalization eﬃciency.
Mechanisms of Cellular Internalization. The internal-
ization mechanism of polyarginine-functionalized delivery
Figure 3. Confocal ﬂuorescence images of MCF-7 cells treated with PA/AON complexes after 24 h. MCF-7 cells treated with PA/AON complexes
(a) K-PA/AON, (c) KRSR-PA/AON, (e) R4-PA/AON, (g) R8-PA/AON, (i) R8/KRSR-PA/AON, (k) AON. Merged images of PA/AON
complexes and cells stained with phalloidin and TO-PRO-3 (b) K-PA/AON, (d) KRSR-PA/AON, (f) R4-PA/AON, (h) R8-PA/AON, (j) R8/KRSR-
PA/AON, (l) AON. FAM-AON (red), actins (green), nuclei (blue) (scale bars: 20 μm).
Figure 4. Uptake of PA/AON complexes by MCF-7 cells quantiﬁed
with ﬂow cytometry. (Error bars show SEM; two independent
experiments were repeated with n = 3 in each experiment. One-way
ANOVA shows statistical signiﬁcance with ∗ p < 0.05, ∗∗ p < 0.01,
∗∗∗ p < 0.001.)
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systems has been controversial; however, it has recently been
reported that the pathway utilized mostly depends on the
concentration of the peptide.23 Previously, direct translocation
of arginine rich peptides was thought to be the main
mechanism,24 yet peptides were demonstrated to be taken up
by endocytosis at low concentrations (below 10 μM).25 At high
concentrations, however, the endocytosis-independent mode of
uptake (rapid nuclear zone dependent uptake) was observed to
be the dominant mechanism. This mode of uptake was
reported to be dependent on the dynamin and heparan sulfate
residues on the cell surface.25
Uptake inhibitors were used to study the mechanisms
involved in the internalization of PAs decorated with CPPs and
heparin binding sequences (Figure 5). Amiloride, dynasore,
chlorpromazine, and nystatin were used to inhibit macro-
pinocytosis, dynamin-dependent pathway, clathrin-mediated
endocytosis, and caveolae-mediated endocytosis, respectively.26
The internalization of K-PA and R4-PA was not inhibited with
any of the chemical inhibitors used, which strongly indicates
that the internalization was via a nonendocytotic pathway and
probably through direct translocation. KRSR-PA and R8-PA
internalization, unlike other PAs, was found to be dynamin-
mediated at 30 μM PA concentration. Interestingly, the R8/
Figure 5. Mechanisms of cellular internalization of PA/AON complexes in MCF-7 cells. Amiloride (Amil), Dynasore (Dyna), Chlorpromazine
(Chlor), and Nystatin (Nys) were administered to cells to inhibit endocytosis pathways; uptake was normalized to cells without inhibitor (w/o inh).
(Error bars show SEM; two independent experiments were repeated with n = 3 in each experiment. One-way ANOVA shows statistical signiﬁcance
with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.)
Figure 6. Bcl-2 expression in MCF-7 cells treated with PA/AON or PA/MM complexes. Gene expression was normalized to GAPDH. AON,
antisense oligonucleotide; MM, mismatch control. (Error bars show SEM; two independent experiments were repeated with n = 3 in each
experiment. Student’s t test shows statistical signiﬁcance with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.)
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KRSR-PA complex was demonstrated to be internalized via
clathrin- and caveolae-mediated endocytosis and dynamin-
dependent pathway. Overall, these results demonstrate that the
amino acid sequences presented on the surface of PAs are
critical in modulating the uptake mechanism of PA/AON
complexes.
Gene Expression Analyses. An eﬃcient delivery vehicle
must carry the oligonucleotide into the cell, escape from
endosome, and carry the molecule to the target organelle.
Antisense oligonucleotides (except splice-correction AONs)
bind to target mRNAs in the cytosol to induce translational
arrest. Therefore, Bcl-2 AON would silence Bcl-2 gene
expression only in the presence of an eﬃcient transfection
system that delivers the intact AON into the cytosol. Bcl-2
expression following PA/AON complex administration was
investigated in MCF-7 cells, and all PA/AON complexes except
K-PA/AON were shown to be eﬀective in decreasing the gene
expression (Figure 6). KRSR-PA/AON, R8-PA/AON, and the
combination of these two PAs signiﬁcantly silenced the Bcl-2
gene in MCF-7 cells. The expression decrease in KRSR-PA/
AON, R8-PA/AON, and the combination was comparable to
the lipofectamine control, which is a commercial transfection
agent with a cationic lipid composition. Although the cellular
internalizations of KRSR-PA/AON and R4-PA were only
slightly higher compared to K-PA, delivery with K-PA did
not induce Bcl-2 silencing, which suggests that K-PA could not
provide endosomal escape, whereas KRSR-PA and R4-PA
could. Endosomal escape, which can be facilitated by the
multivalency of the CPPs,27 is a prerequisite for AONs to be
functional. Our PA delivery system presenting multivalent
CPPs on the surface is an example of this strategy, which allows
CPP-decorated PAs to induce the endosomal escape and thus
protect the functionality of their AON cargo.
■ CONCLUSION
Here we designed a bioinspired, biodegradable, and bioactive
oligonucleotide delivery system with self-assembling PAs. The
system was decorated with cell penetrating peptides and a cell
surface binding peptide to increase the cellular internalization
of the oligonucleotide. All bioactive PAs were shown to have
high transfection eﬃciencies, yet the cell surface binding KRSR-
PA is outstanding compared to other delivery systems in
providing both high transfection eﬃciency and low toxicity.
Considering its advantages over other delivery systems, the
designed carrier system holds promise for oligonucleotide
delivery, especially with regards to its ability to self-assemble
into nanostructures and present multivalent CPPs on the
surface through self-assembly. These bioinspired self-assem-
bling systems can provide transfection eﬃciencies comparable
to viral delivery without contamination risk of viral proteins.
These designs can also supersede polymer, lipid, and
nanoparticle-based delivery systems owing to their practical
properties such as simple design and synthesis, facile
functionalization, and high biocompatibility.
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